Neurocrine Biosciences Stock News

Deerfield Management Company, L.P. (Series C), a renowned investment firm, recently made a significant addition to its portfolio.

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Stree

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences: Multiple 2023 Catalysts Makes It A Must-Watch.

As 2023 unfolds, the pharmaceutical space is blossoming with new opportunities, sparking curiosity for those looking to buy some pharma stocks. With the iShares Biotechnology ETF (NASDAQ: IBB ) ticki

Neurocrine Biosciences: Today's Best Near-Term Cap-Gain Biotech Developer Prospect.

Healthcare growth stocks are often sought out by investors looking for market disruptors. That's because these stocks can potentially deliver high revenue growth, earnings, and stock price.

Barclays Global Healthcare Conference on March 15 in Miami Jefferies Biotech on the Bay Summit on March 16 in Miami SAN DIEGO , March 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX

The stock price of Neurocrine Biosciences (NASDAQ: NBIX) fell by 4.55% in the most recent trading session. This is why.

Start Time: 08:00 January 1, 0000 9:02 AM ET Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q4 2022 Earnings Conference Call February 06, 2023, 08:00 AM ET Company Participants Kevin Gorman - CEO Matt Ab

Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences reported strong fourth-quarter profit growth on Monday and beat fourth-quarter estimates. But NBIX stock was flat.

Expect strong Neurocrine Biosciences, Inc. Q4 results on February 6, 2023. Two important pipeline results regarding congenital adrenal hyperplasia and focal onset seizures will be coming this February

After a strong performance in H2 FY22, Neurocrine Biosciences saw a sharp reversal into the new year. The question is, does this present an opportunity to buy or not?

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week